Risk-adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

被引：6

作者：

Pemmaraju, Naveen ^{[1
]}

Harrison, Claire ^{[2
]}

Gupta, Vikas ^{[3
]}

Verstovsek, Srdan ^{[1
]}

Scott, Bart ^{[4
]}

Oh, Stephen T. ^{[5
]}

Palandri, Francesca ^{[6
]}

Al-Ali, Haifa Kathrin ^{[7
]}

Sobas, Marta ^{[8
]}

McMullin, Mary Frances ^{[9
]}

Mesa, Ruben ^{[10
]}

Buckley, Sarah ^{[11
]}

Roman-Torres, Karisse ^{[11
]}

Vannucchi, Alessandro ^{[12
]}

Yacoub, Abdulraheem ^{[13
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Guys & St Thomas NHS Fdn Trust, London, England

[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[4] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] IRCCS Azienda Osped Univ Bologna, IRCCS Azienda Ospedaliero Universitaria Bologna, Bologna, Italy

[7] Univ Hosp Halle, Krukenberg Canc Ctr Halle, Halle, Germany

[8] Wroclaw Med Univ, Dept Hematol Blood Neoplasms & Bone Marrow Transpl, Wroclaw, Poland

[9] Queens Univ Belfast, Belfast, North Ireland

[10] UT Hlth San Antonio MD Anderson Canc Ctr, San Antonio, TX USA

[11] CTI Biopharm, Seattle, WA USA

[12] Univ Florence, Azienda Osped Univ Careggi, Florence, Italy

[13] Univ Kansas Canc Ctr, Westwood, KS USA

来源：

EJHAEM | 2022年 / 3卷 / 04期

关键词：

myelofibrosis; myeloproliferative neoplasms; pacritinib; safety;

D O I：

10.1002/jha2.591

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The safety profile of the novel oral JAK2/IRAK1 inhibitor pacritinib in patients with cytopenic myelofibrosis was described in the Phase 2 PAC203 and Phase 3 PERSIST-2 studies. To account for longer treatment durations on the pacritinib arms compared to best available therapy (BAT), we present a risk-adjusted safety analysis of event rates accounting for different time on treatment. While the rate of overall events was higher on pacritinib compared to BAT, the rate of fatal events was lower, and there was no excess in bleeding, cardiac events, secondary malignancy, or thrombosis on pacritinib, including in patients with severe thrombocytopenia.

引用

页码：1346 / 1351

页数：6

共 50 条

[31] FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS
Seymour, F.
To, B.
Goh, A.
Meadows, L.
Ethirajulu, A.
Wood, A.
Zhu, A.
Roberts, W.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 472 - 472
[32] LONG-TERM FOLLOW UP OF A PHASE 1/2 STUDY OF SAR302503, AN ORAL JAK2 SELECTIVE INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF)
Gotlib, J.
Pardanani, A.
Jamieson, C.
Cortes, J.
Talpaz, M.
Stone, R.
Gao, G.
Zhang, J.
Neumann, F.
Lebedinsky, C.
Tefferi, A.
HAEMATOLOGICA, 2012, 97 : 145 - 145
[33] Comprehensive Kinase Profile of Pacritinib, a Non-Myelosuppressive JAK2 Kinase Inhibitor in Phase 3 Development in Primary and Post ET/PV Myelofibrosis
Singer, Jack
Al-Fayoumi, Suliman
Ma, Haiching
Komrokji, Rami S.
Mesa, Ruben
Verstovsek, Srdan
BLOOD, 2014, 124 (21)
[34] The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
Ikeda, Kazuhiko
Ueda, Koki
Sano, Takahiro
Ogawa, Kazuei
Ikezoe, Takayuki
Hashimoto, Yuko
Morishita, Soji
Komatsu, Norio
Ohto, Hitoshi
Takeishi, Yasuchika
INTERNAL MEDICINE, 2017, 56 (13) : 1705 - 1710
[35] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
Pardanani, Animesh
Gotlib, Jason
Gupta, Vikas
Roberts, Andrew W.
Wadleigh, Martha
Sirhan, Shireen
Bavisotto, Linda M.
Kawashima, Jun
Kowalski, Mark
Tefferi, Ayalew
BLOOD, 2012, 120 (21)
[36] The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
V Novotny-Diermayr
S Hart
K C Goh
A Cheong
L-C Ong
H Hentze
M K Pasha
R Jayaraman
K Ethirajulu
J M Wood
Blood Cancer Journal, 2012, 2 : e69 - e69
[37] The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
Novotny-Diermayr, V.
Hart, S.
Goh, K. C.
Cheong, A.
Ong, L-C
Hentze, H.
Pasha, M. K.
Jayaraman, R.
Ethirajulu, K.
Wood, J. M.
BLOOD CANCER JOURNAL, 2012, 2 : e69 - e69
[38] SAFETY OVERVIEW OF PHASE I-II STUDIES OF PACRITINIB, A NON-MYELOSUPPRESSIVE JAK2/FLT3 INHIBITOR, IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
Verstovsek, S.
Liang, S.
Komrokji, R.
Mesa, R.
Seymour, J.
Dean, J.
Wang, L.
Singer, J.
Myint, H.
Younes, A.
HAEMATOLOGICA, 2013, 98 : 119 - 120
[39] BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis
Pardanani, Animesh
Roberts, Andrew W.
Seymour, John F.
Burbury, Kate
Verstovsek, Srdan
Kantarjian, Hagop M.
Begna, Kebede
Yoshitsugu, Hiroyuki
Gestone, Toni Ann
Phillips, Penny
Xing, Guan
Peltz, Gerson
Lorenzi, Matthew V.
Alland, Leila
Woolfson, Adrian
Tefferi, Ayalew
BLOOD, 2013, 122 (21)
[40] Activity Of a JAK1/JAK2 Inhibitor In a Patient With KIT-Mutated Systemic Mastocytosis (SM) Associated With Myelofibrosis
Santos, Fabio P. S.
Helman, Ricardo
Pereira, Welbert O.
Puga, Renato D.
Nakashima, Sandra S.
Bello, Isabel C.
Diniz, Michelli S.
Hamerschlak, Nelson
Campregher, Paulo Vidal
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →